Literature DB >> 19749990

Advances in vaccine technology and their impact on managed care.

Jonathan A McCullers, Jeffrey D Dunn.   

Abstract

The discovery of vaccines has led to the near eradication of several important diseases and has had a tremendous impact on health for a relatively low cost. However, most vaccines in use today were developed by techniques that were pioneered more than 100 years ago and do not represent the full potential of the field. The introduction of genetic engineering has fueled rapid advances in vaccine technology and is now leading to the entry of new products in the marketplace.In the past, options for the utilization of vaccines in the area of managed care had been quite limited because of the historically straightforward application of immunizations. The growing number and type of vaccine targets, coupled with novel, more effective formulations, adjuvants, and routes of delivery for vaccines, will undoubtedly create new challenges. Although progress in vaccine technology has the potential to prevent illness and reduce the economic burden of diseases in the long term, thereby improving outcomes, ongoing problems remain in the short term.Who should and will pay for these anticipated improvements in health?How will this period of change be managed?This article describes the present "vaccine revolution" and attempts to answer these questions, which are becoming increasingly important in managed care.

Entities:  

Keywords:  adjuvant; genetic engineering; managed care; technology; vaccine

Year:  2008        PMID: 19749990      PMCID: PMC2730064     

Source DB:  PubMed          Journal:  P T        ISSN: 1052-1372


  33 in total

1.  Impact of vaccines universally recommended for children--United States, 1990-1998.

Authors: 
Journal:  MMWR Morb Mortal Wkly Rep       Date:  1999-04-02       Impact factor: 17.586

Review 2.  Use of viral vectors for the development of vaccines.

Authors:  Matthias Liniger; Armando Zuniga; Hussein Y Naim
Journal:  Expert Rev Vaccines       Date:  2007-04       Impact factor: 5.217

3.  Needle-free skin patch delivery of a vaccine for a potentially pandemic influenza virus provides protection against lethal challenge in mice.

Authors:  Sanjay Garg; Mary Hoelscher; Jessica A Belser; Chong Wang; Lakshmi Jayashankar; Zhu Guo; Ross H Durland; Jacqueline M Katz; Suryaprakash Sambhara
Journal:  Clin Vaccine Immunol       Date:  2007-05-09

4.  Antigen sparing and cross-reactive immunity with an adjuvanted rH5N1 prototype pandemic influenza vaccine: a randomised controlled trial.

Authors:  Isabel Leroux-Roels; Astrid Borkowski; Thomas Vanwolleghem; Mamadou Dramé; Frédéric Clement; Eliane Hons; Jeanne-Marie Devaster; Geert Leroux-Roels
Journal:  Lancet       Date:  2007-08-18       Impact factor: 79.321

5.  Lack of adjuvant effect of A1PO4 on purified influenza virus hemagglutinins in man.

Authors:  F M Davenport; A V Hennessy; F B Askin
Journal:  J Immunol       Date:  1968-05       Impact factor: 5.422

6.  Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared to aluminium salt only.

Authors:  Sandra L Giannini; Emmanuel Hanon; Philippe Moris; Marcelle Van Mechelen; Sandra Morel; Francis Dessy; Marc A Fourneau; Brigitte Colau; Joann Suzich; Genevieve Losonksy; Marie-Thérèse Martin; Gary Dubin; Martine A Wettendorff
Journal:  Vaccine       Date:  2006-06-19       Impact factor: 3.641

Review 7.  Rotavirus vaccines--an update.

Authors:  Penelope H Dennehy
Journal:  Vaccine       Date:  2007-02-09       Impact factor: 3.641

8.  Mucosal immunization of rhesus monkeys against respiratory syncytial virus subgroups A and B and human parainfluenza virus type 3 by using a live cDNA-derived vaccine based on a host range-attenuated bovine parainfluenza virus type 3 vector backbone.

Authors:  Alexander C Schmidt; Daniel R Wenzke; Josephine M McAuliffe; Marisa St Claire; William R Elkins; Brian R Murphy; Peter L Collins
Journal:  J Virol       Date:  2002-02       Impact factor: 5.103

9.  Eight-plasmid system for rapid generation of influenza virus vaccines.

Authors:  Erich Hoffmann; Scott Krauss; Daniel Perez; Richard Webby; Robert G Webster
Journal:  Vaccine       Date:  2002-08-19       Impact factor: 3.641

10.  Prevention and control of influenza. Recommendations of the Advisory Committee on Immunization Practices (ACIP), 2007.

Authors:  Anthony E Fiore; David K Shay; Penina Haber; John K Iskander; Timothy M Uyeki; Gina Mootrey; Joseph S Bresee; Nancy J Cox
Journal:  MMWR Recomm Rep       Date:  2007-07-13
View more
  9 in total

Review 1.  Recent Update of COVID-19 Vaccines.

Authors:  Sameer A Jadaan; Abdul Waheed Khan
Journal:  Adv Pharm Bull       Date:  2021-10-04

Review 2.  The Influence of Vaccine on Febrile Seizure.

Authors:  Xin Li; Yang Lin; Gang Yao; Yicun Wang
Journal:  Curr Neuropharmacol       Date:  2018       Impact factor: 7.363

3.  Early use of the HPV 2-dose vaccination schedule: Leveraging evidence to support policy for accelerated impact.

Authors:  Vladimir Gilca; Jorge Salmerón-Castro; Chantal Sauvageau; Gina Ogilvie; Monique Landry; Monica Naus; Eduardo Lazcano-Ponce
Journal:  Vaccine       Date:  2018-06-07       Impact factor: 3.641

4.  Humoral immunity in leishmaniasis - Prevention or promotion of parasite growth?

Authors:  Ricardo Goncalves; Stephen M Christensen; David M Mosser
Journal:  Cytokine X       Date:  2020-10-31

5.  Potential Application of Exosomes in Vaccine Development and Delivery.

Authors:  Md Nurul Huda; Md Nurunnabi
Journal:  Pharm Res       Date:  2022-01-13       Impact factor: 4.580

Review 6.  Liposome-polymer complex for drug delivery system and vaccine stabilization.

Authors:  Abd Kakhar Umar; Nasrul Wathoni; James H Zothantluanga; Sanjoy Das; Jittima Amie Luckanagul
Journal:  Heliyon       Date:  2022-02-12

Review 7.  Ionizing Radiation Technologies for Vaccine Development - A Mini Review.

Authors:  Sohini S Bhatia; Suresh D Pillai
Journal:  Front Immunol       Date:  2022-02-11       Impact factor: 7.561

Review 8.  Development of variant-proof severe acute respiratory syndrome coronavirus 2, pan-sarbecovirus, and pan-β-coronavirus vaccines.

Authors:  Jie Zhou; Zezhong Liu; Guangxu Zhang; Wei Xu; Lixiao Xing; Lu Lu; Qian Wang; Shibo Jiang
Journal:  J Med Virol       Date:  2022-09-25       Impact factor: 20.693

Review 9.  Protein Supramolecular Structures: From Self-Assembly to Nanovaccine Design.

Authors:  Ximena Zottig; Mélanie Côté-Cyr; Dominic Arpin; Denis Archambault; Steve Bourgault
Journal:  Nanomaterials (Basel)       Date:  2020-05-25       Impact factor: 5.076

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.